Manuscript template
Prepare the main manuscript and keep author identities in the separate title page.
Download manuscript templateFor authors
A practical route through scope, manuscript files, scientific reporting and the declarations needed for a fair review.
Prepare an accurate AI-use declaration, verify references and explain the provenance of figures, data and code.
Recommended before submission. Check sections, declarations, citations and references, then prepare a Word draft with this journal’s template.
The journal is led by Editor-in-Chief Dr. Thierry Oscar Codjo Edoh. Manuscript reception remains closed while the submission workflow is prepared. You may use the guidance and Manuscript Pre-check to prepare your work; preparation is not a journal submission. The opening date and authorised submission route will be announced here.
Downloading a template or preparing evidence does not submit a manuscript. The formal submission route will be announced when the journal opens.
Use these editable files alongside the instructions below. They are preparation resources; they do not create an active submission.
Prepare the main manuscript and keep author identities in the separate title page.
Download manuscript templateRecord the author list, affiliations, contributions and relevant declarations separately.
Download title pageExplain the contribution, journal fit and related work for editorial assessment.
Download cover letterAddress each review point and identify revisions or explain a reasoned disagreement.
Download response to reviewersPrepare an anonymised manuscript, a separate title page, a cover letter and any supporting files needed to assess the work. The title page should give the full journal title, manuscript title, article type, author names and affiliations, corresponding author details, contribution statement and relevant declarations. Keep identities and identifying acknowledgements out of the review manuscript. Anonymise document properties and explain any repository link that could reveal authorship. Ethics, data-access and methodological declarations needed to assess the science must remain in anonymised form in the review manuscript. Provide identifying approvals or other confidential evidence separately through the authorised editorial route.
Prepare an editable DOCX manuscript using the journal structure; a review PDF may accompany it. Authors using LaTeX or another specialist format should seek an agreed alternative route before submission and provide a compiled review PDF and source when requested. Supply original figure files and an accurate reference list for production. Initial submissions may use a consistent readable reference style. The final house style is specified during production. References to data and software should identify the version or release and a persistent identifier where available.
Use a specific title, an informative abstract and descriptive keywords. State the research question, its relationship to prior work, the methods and assumptions, the evidence, limitations and conclusions. For empirical work, distinguish results from interpretation. For theoretical, conceptual or qualitative work, use a structure that makes the reasoning and evidence traceable. Include all applicable declarations and cite supplementary material in the manuscript.
There is no fixed initial-submission word limit in this guide. Provide a word count and use the length needed for a complete, focused account. The editor may request shortening or restructuring. A later published article-type limit will apply to submissions received after its stated effective date; any exceptional change for a manuscript already under consideration must be communicated to its authors.
A preparation file or saved evidence record does not constitute a journal submission. Formal submission requires the journal's announced submission route, author approval and completion of the required declarations. Authors should use the manuscript reference in subsequent correspondence and identify the version to which a query relates.
A revised submission should include an updated anonymised manuscript, any revised supporting files and a response addressing every editorial and reviewer point. Identify where changes were made and explain any reasoned disagreement. Keep the response professional and provide evidence for disputed technical issues. Do not silently substitute datasets, analyses or author lists; disclose consequential changes for editorial assessment.
Journal-specific standards
Use the guidance relevant to your design. A formal, conceptual or behavioural study should not add unrelated experiments merely to resemble another article type.
Explain who or what may benefit, the care or population context and the gap addressed. For a technology, identify whether the work concerns development, analytical validation, clinical validation, implementation or evaluation of outcomes. These stages answer different questions. Describe the proposed role of the technology and the decisions it could support without presenting investigational findings as established clinical practice.
Choose reporting guidance appropriate to the design and provide a completed checklist where applicable. Examples include CONSORT for randomised trials, STROBE for observational research, PRISMA for evidence syntheses and SRQR or COREQ for relevant qualitative designs. Use relevant extensions for AI, diagnostics, prediction or economic evaluation. A reporting checklist helps readers locate information; it does not establish that the design or conclusions are valid.
Identify the responsible ethics body and approval or exemption reference, or explain the documented basis for a determination that review was not required. State how participation consent was obtained or waived. Research permission, participation consent and consent to publish identifiable information are distinct matters. Describe additional safeguards for vulnerable participants. For relevant animal or biological-material research, provide the applicable welfare, review and collection permissions.
For research meeting the definition of a clinical trial, state its registry, identifier and registration timing. Prospective registration should precede participant enrolment. Explain any late registration and its implications for selective reporting. Supply the protocol and relevant statistical analysis plan, with amendment dates and reasons. Account for changed outcomes, recruitment targets and analyses. Clearly label exploratory or post-hoc analyses and identify relevant harms, withdrawals and missing outcomes.
For quantitative work, explain sample-size reasoning, outcome definitions, missing data, exclusions, confounding, multiplicity and uncertainty. Report effect sizes and intervals where appropriate. For qualitative work, identify the methodological approach, researcher position, sampling, setting, collection, analysis and evidence supporting interpretations. Explain the basis for judging the adequacy of the material. Mixed-method studies should describe why approaches were combined and how findings were integrated.
Include a statement explaining whether and how patients, carers or public representatives influenced the question, design, recruitment, interpretation or dissemination. If there was no involvement, state this without inventing participation. Distinguish involvement in designing research from enrolment as a study participant. For research involving local or Indigenous communities, explain relevant permissions, community priorities, collaboration and decisions about knowledge, data and dissemination.
Explain recruitment, inclusion criteria and the basis for population categories, including sex, gender, ethnicity, age or disability where relevant. Use terms appropriate to the communities concerned and distinguish concepts that measure different attributes. Justify exclusions or restricted populations. Examine important subgroup differences when the design and data support such analysis, and describe limits when they do not. Avoid treating a convenience sample as representative of every intended user.
Explain data provenance, permissions, de-identification and access conditions for both newly collected and reused material. Public availability does not remove consent, licence or ethical obligations. For controlled data, specify the reason for restriction, available materials, eligible applicants, request contact, assessment process, expected response period, permitted uses and access duration where known. Describe relevant agreements and how authorised reviewers can examine the evidence. Report material, reagent or cell-line provenance and authentication when applicable.
Separate development, tuning and testing at the level needed to prevent leakage, including repeated observations from the same person or institution. Explain reference standards, comparators, calibration, discrimination, uncertainty and subgroup assessment as relevant. State the independence and setting of validation and any limits on transportability. External or prospective evaluation should match the deployment claims made. Describe human oversight, failure modes and what remains untested about usability, safety or patient benefit.
Explain the practical meaning of findings for patients, clinicians or services without overstating causation, effectiveness or readiness. Describe important limitations, including small samples, incomplete follow-up or constrained evaluation environments. Identify the relationship between statistical significance and clinical importance. A concise accessible explanation of the findings can support communication with participants and communities; it must retain the uncertainty and limits of the research.
Adapt these examples to what actually occurred. Keep science-relevant information in the anonymised manuscript and provide identifying evidence separately when needed.
The study was reviewed by [full ethics body] under reference [identifier], dated [date]. Participation consent was [obtained in the stated form/waived by the named body]. The basis and scope of any waiver were [explanation]. Replace each field with the actual determination.
The manuscript contains [description of potentially identifiable material]. Written consent for publication was obtained from [the participant or authorised representative] for [scope of material]. Where no identifiable material is included, state the appropriate basis instead of claiming consent that was not obtained.
[Patients/carers/public representatives] contributed to [specific stages and decisions]. Their involvement changed [specific aspect, if applicable]. Findings will be shared through [appropriate route]. Alternatively: Patients and public representatives were not involved in the design or conduct of this study; [brief explanation where useful].
The data contain [reason for restriction] and cannot be released publicly under [actual permission or agreement]. Requests for [specified materials] may be assessed by [responsible body] through [verified route], using [eligibility and permitted-use criteria]. The anticipated response period and access duration are [actual arrangements].
The study was registered at [registry] under [identifier] on [date], [before/after] first enrolment. Changes from the protocol or analysis plan were [description], made on [date] for [reason]. Analyses not specified in advance are identified as exploratory in [location].
Publishing information
Read the journal’s publication frequency, charges, editorial policies and discovery information.